Yahoo Finance’s Alexis Christoforous , Brian Sozzi and Dan Howley discuss Samsung’s new flip-smartphone on The First Trade.

from Yahoo Finance https://ift.tt/3ju6hlA

Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Anjalee Khemlani discuss the latest coronavirus news with with Dr. Anand Parekh, Bipartisan Policy Center Chief Medical Advisor.

from Yahoo Finance https://ift.tt/3juMpik

Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Jessica Smith discuss the latest happenings in the U.S-China relations.

from Yahoo Finance https://ift.tt/2EcsEMl

Since the start of July, the major cruise lines have ramped up their public-facing efforts to safely resume sailing. Norwegian Cruise Lines and Royal Caribbean have co-founded a Healthy Sail Panel with experts across the medical, public health, and epidemiological fields. Carnival has teamed up with the World Travel and Tourism Council for a July 28 […]

from Yahoo Finance https://ift.tt/3hs10cs

Ford and RTR teamed up to bring the Mustang Mach-E prototype to life. The car has seven motors and can generate 1,400 horsepower.

from Yahoo Finance https://ift.tt/3hrw4cn

Investors who once overwhelmingly expected President Donald Trump to be reelected have increasingly resigned themselves to the prospect of a Joe Biden presidency.

from Yahoo Finance https://ift.tt/3eRecpF

(Bloomberg) — U.S. health officials agreed pay $1.95 billion for 100 million doses of a vaccine made by Pfizer Inc. and BioNTech SE, the latest step in an effort to fight the coronavirus pandemic.The companies will receive payment upon the receipt of the doses, following regulatory authorization or approval, according to a statement. The government also can acquire up to an additional 500 million doses.Nations around the world have begun ordering vaccines that are still being tested as part of their efforts to try to blunt the impact of the pandemic that’s roiled economies and killed more than 600,000 people since the beginning of the year. The U.S. has already ordered experimental shots developed by the University of Oxford and AstraZeneca Plc.The vaccine would be available to the American people for free, according to the government. Pfizer shares rose more than 5% in pre-market trading. BioNTech climbed about 7%.(Updates with other orders in the third paragraph. An earlier version of the story corrected the number of doses.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

from Yahoo Finance https://ift.tt/32KK5Oe

WATERLOO, Ontario, July 22, 2020 /CNW/ — BlackBerry Limited (NYSE: BB; TSX: BB) today announced that it has obtained consents from the beneficial owners of 88.39% of its outstanding 3.75% unsecured convertible debentures (TSX: BB.DB.V) (the “3.75% Debentures”) including Fairfax Financial Holdings Limited and certain of its affiliates (together, “Fairfax”), to give effect to an extraordinary resolution (the “Extraordinary Resolution”) authorizing a supplemental indenture to permit the optional redemption of the 3.75% Debentures prior to November 13, 2020. The outstanding principal amount of the 3.75% debentures is US$605 million. BlackBerry intends to redeem the entire outstanding principal amount of the 3.75% Debentures on or about September 1, 2020 (the “Redemption Date”) at a redemption price of 101.6854% of the outstanding principal amount of the 3.75% Debentures.

from Yahoo Finance https://ift.tt/2CTkyaL

Pfizer Inc (PFE) and BioNTech SE (BNTX) have agreed to provide the US government with 100 million doses of their COVID-19 vaccine candidate BNT162, after Pfizer successfully manufactures and obtains approval or emergency use authorization from the US Food and Drug Administration (FDA).The U.S. government will pay the companies $1.95 billion upon the receipt of the first 100 million doses, following FDA authorization or approval. The U.S. government also can acquire up to an additional 500 million doses.Shares in Pfizer are up 5% in Wednesday’s pre-market trading while BioNTech is up 6%.“Expanding Operation Warp Speed’s diverse portfolio by adding a vaccine from Pfizer and BioNTech increases the odds that we will have a safe, effective vaccine as soon as the end of this year,” said Department of Health and Human Services’ Secretary Alex Azar.Americans will receive the vaccine for free following the US government’s commitment for free access for COVID-19 vaccines.The BNT162 program is based on BioNTech’s proprietary mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities. The BNT162 vaccine candidates are undergoing clinical studies and are not currently approved for distribution anywhere in the world.BioNTech is the market authorization holder worldwide and will hold all trademarks for the potential product.The Pfizer/BioNTech vaccine development program is evaluating at least four experimental vaccines, each of which represents a unique combination of messenger RNA (mRNA) format and target antigen. On July 1, Pfizer and BioNTech announced preliminary data from BNT162b1, the most advanced of the four mRNA formulations.The early data demonstrates that BNT162b1 is able to produce neutralizing antibodies in humans at or above the levels observed in the plasma from patients who have recovered from COVID-19, and this was shown at relatively low dose levels. No serious adverse events were reported. On July 20, the companies announced early positive update from German Phase 1/2 COVID-19 vaccine study, including first T Cell response data.If ongoing studies are successful, Pfizer and BioNTech expect to be ready to seek Emergency Use Authorization or some form of regulatory approval as early as October 2020. The companies currently expect to manufacture globally up to 100 million doses by the end of 2020 and potentially more than 1.3 billion doses by the end of 2021.Shares in Pfizer are down 6% year-to-date, while BioNTech has exploded over 170%. Looking forward, analysts take a cautiously optimistic Moderate Buy consensus on both stocks. However, due to the recent rally, BioNTech’s average analyst price target of $60 now indicates 30% downside potential from current levels.Mizuho Securities analyst Vamil Divan has a buy rating on Pfizer and $38 price target (4% upside potential). That’s slightly under the stock’s average analyst price target of $41 (13% upside potential).“We had several discussions with investors today on the back of the initial data, with much of the discussion focused on the commercial potential for a successful SARS-CoV-2 vaccine” the analyst wrote.“The company has mentioned that it will look to price a potential vaccine in line with other commercially-available vaccines, suggesting to us a potential blockbuster commercial opportunity, depending on the vaccine’s clinical profile and the ultimate competitive landscape” he told investors, after the release of ‘encouraging’ early data. (See Pfizer stock analysis on TipRanks)Related News: NuVasive Spikes 5% After-Hours On Sharp Procedure Rebound Intuitive Surgical Delivers Strong Quarter; But Analyst Says Sell Now Is Novavax’s (NVAX) Super-High Valuation Justified? This Analyst Says ‘Yes’TopicsBIONTECHBNTXPFEPFIZERLatest NewsAMC Lenders Allege Debt Default Following Silver Lake Deal- Report14mEricsson, Deutsche Telekom Sign Multi-Year 5G Deal; Analyst Bullish On ERIC43mLockheed Martin Beats Quarterly Estimates, Raises 2020 Outlook1hCheck Point Profit Tops Estimates Fueled By Remote Work Push1hBest Buy Pops 5% On Strong Online Sales; Top Analyst Ramps Up PT1hUnited Airlines Gains in After-Hours Despite $2.6 Billion Quarterly Loss1hAlphabet’s Waymo Expands Chrysler Partnership To Driverless Minivans2hPhillip Morris Beats Quarterly Estimates3hSEE MORETipRanks BlogWhich Leading Financial Blog Has the Best Bloggers?July 16, 2020Nasdaq Trade Talks Interviews TipRanks CEOJuly 15, 2020Meet the TipRanks Team – Eyal Gershon, Head of Product and UXJuly 15, 2020SEE MOREMore ArticlesAMC Lenders Allege Debt Default Following Silver Lake Deal- Report14 minutes agoEricsson, Deutsche Telekom Sign Multi-Year 5G Deal; Analyst Bullish On ERIC44 minutes agoLockheed Martin Beats Quarterly Estimates, Raises 2020 Outlook1 hour agoSEE MORE More recent articles from Smarter Analyst: * AMC Lenders Allege Debt Default Following Silver Lake Deal- Report * Ericsson, Deutsche Telekom Sign Multi-Year 5G Deal; Analyst Bullish On ERIC * Check Point Profit Tops Estimates Fueled By Remote Work Push * Best Buy Pops 5% On Strong Online Sales; Top Analyst Ramps Up PT

from Yahoo Finance https://ift.tt/3hqEIYC

Ericsson (ERIC) and Deutsche Telekom AG (DTEGY) have announced an expanded partnership with a new multi-year deal to deploy the service provider’s 5G Radio Access Network (RAN) across Germany.Under the terms of the deal, several mobile sites will be upgraded to the latest 5G technology standard over the next few years using Ericsson Radio System products and solutions. The 5G deal is in addition to a multi-RAN agreement following modernization of Deutsche Telekom’s 2G, 3G and 4G radio networks over the past two years.ERIC’s Spectrum Sharing solution will also be deployed, allowing Deutsche Telekom to dynamically manage 4G and 5G traffic in its network through efficient use of existing spectrum, enhancing coverage, performance and mobility.Claudia Nemat of Deutsche Telekom AG commented: “We are pleased to have found a leading 5G supplier in Ericsson as a partner, who has also convinced us in the past in the modernization of our mobile access network. After the reliable and on-time modernization, the bar for the 5G roll-out in the antenna network is naturally also high.”As well as public mobile networks, the two companies also work closely together when it comes to equipping industrial companies with private mobile networks, so-called campus networks. Most recently, the partners jointly equipped individual BMW and Osram (OSAGF) plant sites.Deutsche Telekom, the largest telecom service provider in Europe by revenue, has seen shares climb by 9% year-to-date, while Ericsson has surged 34%. Looking ahead, ERIC scores a Strong Buy Street consensus, with Deutsche Telekom showing a slightly more subdued Moderate Buy consensus.Speaking for the bulls, Charter Equity’s Edward Snyder wrote on July 17 “COVID notwithstanding, 2020 is playing out well for Ericsson.” He made the comment after Ericsson reported a $0.03 beat for the June quarter on strong 5G demand in North America and China. Impact from COVID-19 was minimal in the June period while demand for 5G equipment was strong in North America and China.Management doesn’t provide financial guidance, but according to Snyder, conference call comments suggest September period (3Q20) revenue and EPS of $6.3B and $0.17 respectively, above consensus revenue and EPS estimates of $6B and $0.15.The analyst continued: “The lumpy nature of network rollouts makes revenue timing difficult to predict, but between the timing of deployments in China, the U.S. and Europe and changes in the competitive environment, Ericsson’s fortunes in 5G are improving and already off to a strong start in 2020.” (See ERIC stock analysis on TipRanks)Related News: Logitech Ramps Up Annual Profit Outlook As Q1 Income Leaps 75% Synaptics Snaps Up DisplayLink For $305M In All-Cash Deal Texas Instruments Provides Upbeat Sales Outlook; Top Analyst Sees 18% Upside More recent articles from Smarter Analyst: * Check Point Profit Tops Estimates Fueled By Remote Work Push * Best Buy Pops 5% On Strong Online Sales; Top Analyst Ramps Up PT * Alphabet’s Waymo Expands Chrysler Partnership To Driverless Minivans * Two Harbors Ends Management Agreement, Citing Material Breaches

from Yahoo Finance https://ift.tt/3eM1Ej3